- Home
- Evonik Interview: How Recombinant Albumin De-Risks Cell Therapy Manufacturing
Evonik Interview: How Recombinant Albumin De-Risks Cell Therapy Manufacturing
Published on 19 July 2026
InVitria + Evonik Partnership Spotlight: Recombinant HSA for Reliable Cell & Gene Therapy Scale-Up
Author: Evonik, Featured Experts: Jake Hanks, Director of Business Development, InVitria & Sabrina Metze, Evonik
Source: Evonik News, July 2026

Introduction Our partner Evonik has published a detailed interview featuring InVitria’s Director of Business Development, Jake Hanks. The discussion focuses on how recombinant human serum albumin helps biopharma manufacturers reduce risks in cell therapy production through greater consistency, purity, and supply security.
Full Interview Link Read the complete Evonik interview
Partnership Overview Evonik distributes InVitria’s recombinant human albumin portfolio globally under the CreaCyte® brand. This includes:
- Cellastim® S – Lyohpilized powder for cell culture media & upstream use
- Exbumin® – Lyophilized powder Excipient-grade for formulation stability
- Optibumin® 20 & Optibumin® 25 – Ready-to-use excipient grade liquid solutions for biomanufacturing, 20 & 25% w/v
Key Benefits Highlighted
- Chemically defined, animal-origin-free alternative to plasma-derived HSA
- Superior lot-to-lot consistency and purity
- Closed-system compatible packaging (Optibumin® 25 in sterile 100 mL bags)
- Enhanced supply chain security for commercial-scale programs
- Strong regulatory alignment (cGMP, ISO 9001, FDA/EMA familiarity)
Key Quotes
“Evonik is distributing our recombinant human albumin portfolio globally under the CreaCyte® brand… Combined with Evonik’s global reach, this allows us to support customers from early development through to commercialization.” — Jake Hanks, Director of Business Development, InVitria
“Optibumin® 25 is the first recombinant human serum albumin available as a 25% liquid solution… a true replacement in both format and concentration.” — Jake Hanks, InVitria
As cell and gene therapies scale, reliable raw materials become critical. Recombinant albumin eliminates variability and contamination risks associated with blood-derived sources while enabling seamless integration into GMP closed-system workflows.
Ready to explore recombinant albumin for your process?
View Recombinant Albumin here: https://invitria.com/type/recombinant-human-albumin/
Footnotes
- Evonik Interview – Link
- InVitria CreaCyte® / Optibumin® product data